Tumor Size Reduction
A skin cancer drug developed at the Genetic Engineering and Biotechnology Center (Havana) has received approval for marketing.
Heberferon is a unique combination of interferon alpha and interferon gamma, a genetically engineered drug developed at the Cuba Research Center. Clinical trials which lasted for 20 years confirmed the efficacy and safety of the drug, supporting its authorization for marketing.
According to one of the researchers of the drug biologist Iraldo Belio, this injectable drug helps reduce the size of all tumors on skin (excluding melanomas), helping avoid surgical intervention on the patient’s face.
Effects of the drug are currently being studied for other types of cancers.